ERBB3 and breast cancer: This research showed that pertuzumab blocks the association of HER2 and HER3, diminishes ligand-activated HER2 signaling including Erk activation, and inhibits the growth of human breast cancer cell lines only in the presence of ligand (heregulin) [171].